Comments
The US-based BioMarin Pharmaceutical Inc has settled its on-going patent dispute with Hyderabad-based Dr Reddy’s Laboratories Ltd on Kuvan (sapropterin dihydrochloride).
An agreement was inked by the two parties in this regard, BioMarin said in statement on its portal.
As part of the pact, BioMarin will grant Dr Reddy’s a non-exclusive licence to market a generic version of Kuvan tablets in the due course.
Kuvan has clocked $203 million revenue for the company in 2014. It is indicated for the treatment of hyperphenylalaninemia (HPA) in adults and children with phenylketonuria (PKU).
HPA is the most frequently inherited disorder of amino acid metabolism.
“The settlement agreement recognises the strength of the intellectual property related to Kuvan and helps ensure that patients, who depend on Kuvan to manage their phenylketonuria (PKU), will continue to receive the medication and the range of support services offered to patients for years to come,” said Executive Vice-President and Chief Commercial Officer, BioMarin Jeff Ajer.
In January 2015, BioMarin had filed a lawsuit in the US District Court for the southern district of New York, against Dr Reddy’s for the drug. As required by law, BioMarin and Dr Reddy’s will submit the agreement to the US Federal Trade Commission and the US Department of Justice, the statement further said.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.